Skip to main content
Premium Trial:

Request an Annual Quote

PierianDx Closes Equity Financing, Loan Facility for up to $47.5M

NEW YORK – PierianDx announced on Tuesday that it had closed $30 million of growth capital in the form of equity financing and a term loan facility, with access to additional tranches of up to $17.5 million by 2022 and 2023.

OrbiMed led the current investment round, with existing investors Health Catalyst Capital, Research Triangle Institute, Inova Health Systems, ATW Partners, and SJF Ventures also participating. The new financing is expected to drive PierianDx's commercial expansion as healthcare organizations bring next-generation sequencing capabilities in house, the St. Louis-based firm said.

Founded in 2014 as a spinout from Washington University in St. Louis, PierianDx partners with healthcare providers, laboratories, and medical centers to build on-site next-gen sequencing capabilities.

The company recently joined with Illumina and the Belgian Society of Medical Oncology to study the value of genomic profiling among advanced cancer patients. The BSMO is using PierianDx's Clinical Genomics Workspace platform to perform clinical interpretation of NGS results in that study.

PierianDx previously partnered with Illumina on NGS-based cancer panel reporting. The company raised $27 million in a Series B financing round in 2019.

The Scan

For STEM Students to Stay

New policy changes will make it easier for international STEM students to stay in the US after graduation, the Wall Street Journal reports.

To Inform or Not, To Know or Not

The New York Times writes that some genetic biobanks may re-contact donors if they spot something troublesome, but it notes that not all donors want that information.

Rapid Test Studies

Researchers are examining why rapid tests may be less effective at detecting the Omicron variant and how to improve them, NPR says.

PLOS Papers on SARS-CoV-2 Diversity in Delaware, Metastatic Breast Cancer, Adiposity GWAS

In PLOS this week: genomic analysis of SARS-CoV-2 isolates from Delaware, gene expression and protein-protein interaction patterns in metastatic breast cancer, and more.